{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:39:36Z","timestamp":1792543176520,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["10002556"],"award-info":[{"award-number":["10002556"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcf.2025.12.016","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T11:53:29Z","timestamp":1766663609000},"page":"262-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Improved ventilation inhomogeneity and lower LCI variability under ETI: Retrospective analysis in a pediatric cohort"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2342-9710","authenticated-orcid":false,"given":"Tabitha","family":"Arn-Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9118-1360","authenticated-orcid":false,"given":"Tessa","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9519-9328","authenticated-orcid":false,"given":"Bettina Sarah","family":"Frauchiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6184-5280","authenticated-orcid":false,"given":"Insa","family":"Korten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Casaulta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kieninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5239-1571","authenticated-orcid":false,"given":"Philipp","family":"Latzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2025.12.016_bib0001","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2025.12.016_bib0002","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0003","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-term safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in children aged \u2a7e6 years with cystic fibrosis and at least one F508del Allele: a phase 3, open-label clinical trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of Elexacaftor\/Tezacaftor\/Ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0005","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.230084","article-title":"Lung function in patients with cystic fibrosis before and during CFTR-modulator therapy using 3D ultrashort echo time MRI","volume":"308","author":"Heidenreich","year":"2023","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.jcf.2025.12.016_bib0006","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcf.2025.01.004","article-title":"Short-term modification of breathprint by Elexacaftor\/Tezacaftor\/Ivacaftor in a paediatric cohort","volume":"24","author":"Bardin","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2025.12.016_bib0007","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1513\/AnnalsATS.202501-103OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in 6 to 11-year-olds with cystic fibrosis","volume":"22","author":"Pittman","year":"2025","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.jcf.2025.12.016_bib0008","doi-asserted-by":"crossref","first-page":"2400004","DOI":"10.1183\/13993003.00004-2024","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles","volume":"64","author":"Stahl","year":"2024","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jcf.2025.12.016_bib0009","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/ppul.26938","article-title":"Lung clearance index (LCI2.5) changes after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in children with cystic fibrosis aged between 6 and 11 years: the \u201creal-world\u201d differs from trial data","volume":"59","author":"Urquhart","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.016_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71166","article-title":"Real-world improvements of lung clearance index and ventilation distribution efficiency in children with cystic fibrosis after Elexacaftor\/Tezacaftor\/ivacaftor initiation","volume":"60","author":"Henriksen","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.12.016_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41390-025-04552-6","article-title":"Effectiveness of elexacaftor\/tezacaftor\/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry","author":"Alicandro","year":"2025","journal-title":"Pediatr Res"},{"issue":"9","key":"10.1016\/j.jcf.2025.12.016_bib0012","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with Elexacaftor\/Tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older - the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.12.016_bib0013","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jcf.2024.09.021","article-title":"Assessing 129Xe multi-breath washout MRI response to elexacaftor\/tezacaftor\/ivacaftor intervention in pediatric CF","volume":"24","author":"Alam","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.12.016_bib0014","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on lung clearance index and Magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.12.016_bib0015","article-title":"PREFUL MRI for monitoring perfusion and ventilation changes after elexacaftor-Tezacaftor-ivacaftor therapy for Cystic fibrosis: a feasibility study","volume":"6","author":"Dohna","year":"2024","journal-title":"Radiol Cardiothorac Imaging"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00408-024-00781-4","article-title":"Respiratory outcomes and Aspergillus serology following Elexacaftor\/Tezacaftor\/ivacaftor therapy in people with cystic fibrosis and a history of Aspergillus fumigatus infection","volume":"203","author":"Lanfranchi","year":"2025","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00408-024-00768-1","article-title":"Lung clearance index improves in people with cystic Fibrosis not achieving a clinical important difference in forced expiratory volume in one second after Elexacaftor\/Tezacaftor\/ivacaftor therapy","volume":"203","author":"Dacc\u00f2","year":"2024","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00330-023-09912-6","article-title":"Effect of CFTR modulator therapy with elexacaftor\/tezacaftor\/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients","volume":"34","author":"Klime\u0161","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jcf.2025.12.016_bib0019","doi-asserted-by":"crossref","first-page":"1125853","DOI":"10.3389\/fphar.2023.1125853","article-title":"Is lung clearance index (LCI) affected by the severity of lung disease in CF?","volume":"14","author":"Appelt","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.12.016_bib0020","first-page":"1","article-title":"The proof of the pudding is in the eating: real-life intra- and extrapulmonary impact of Elexacaftor\/Tezacaftor\/Ivacaftor","author":"Vincken","year":"2025","journal-title":"Respiration"},{"issue":"20","key":"10.1016\/j.jcf.2025.12.016_bib0021","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.3390\/jcm11206160","article-title":"Dynamic perfluorinated gas MRI shows improved lung ventilation in people with cystic fibrosis after Elexacaftor\/Tezacaftor\/ivacaftor: an observational study","volume":"11","author":"Goralski","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jcf.2025.12.016_bib0022","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/17843286.2022.2145684","article-title":"Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation","volume":"78","author":"Vincken","year":"2023","journal-title":"Acta Clin Belg"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0023","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.12.016_bib0024","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jcf.2024.05.010","article-title":"Lung structural and functional impairments in young children with cystic fibrosis diagnosed following newborn screening - A nationwide observational study","volume":"23","author":"Frauchiger","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.016_bib0025","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.03.00049502","article-title":"Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis","volume":"22","author":"Gustafsson","year":"2003","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2025.12.016_bib0026","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thx.2007.077784","article-title":"Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis","volume":"63","author":"Gustafsson","year":"2008","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.jcf.2025.12.016_bib0027","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1513\/AnnalsATS.201905-375OC","article-title":"Comparison of multiple breath washout and spirometry in children with primary ciliary dyskinesia and cystic fibrosis and healthy controls","volume":"17","author":"Kinghorn","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.016_bib0028","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/thx.2010.150375","article-title":"Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF","volume":"66","author":"Owens","year":"2011","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.jcf.2025.12.016_bib0029","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis\u2013a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J Cystic Fibrosis"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ppul.26180","article-title":"Variability of clinically measured lung clearance index in children with cystic fibrosis","volume":"58","author":"Frauchiger","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2025.12.016_bib0031","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single- breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jcf.2025.12.016_bib0032","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1152\/japplphysiol.00338.2021","article-title":"Correction of sensor crosstalk error in Exhalyzer D multiple-breath washout device significantly impacts outcomes in children with cystic fibrosis","volume":"131","author":"Wyler","year":"2021","journal-title":"J Appl Physiol (1985)"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0033","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ppul.25119","article-title":"Multiple breath washout quality control in the clinical setting","volume":"56","author":"Frauchiger","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.016_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157523","article-title":"A systematic approach to multiple breath nitrogen washout test quality","volume":"11","author":"Jensen","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jcf.2025.12.016_bib0035","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1164\/rccm.200605-642ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: pulmonary function testing in preschool children","volume":"175","author":"Beydon","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.jcf.2025.12.016_bib0036","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0037","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.05.00034505","article-title":"General considerations for lung function testing","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2025.12.016_bib0038","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2025.12.016_bib0039","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2025.12.016_bib0040","doi-asserted-by":"crossref","first-page":"2102398","DOI":"10.1183\/13993003.02398-2021","article-title":"Normative multiple-breath washout data in school-aged children corrected for sensor error","volume":"60","author":"Kentgens","year":"2022","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2025.12.016_bib0041","doi-asserted-by":"crossref","first-page":"1700433","DOI":"10.1183\/13993003.00433-2017","article-title":"Inter-test reproducibility of the lung clearance index measured by multiple breath washout","volume":"50","author":"Oude Engberink","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2025.12.016_bib0042","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcf.2022.11.003","article-title":"Estimating the minimum sample size for interventional and observational studies using the lung clearance index as an endpoint(\u2730)","volume":"22","author":"Bowerman","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.12.016_bib0043","article-title":"Changes in respiratory viruses in infancy during the SARS-CoV-2 pandemic: a prospective cohort study","volume":"12","author":"Steinberg","year":"2025","journal-title":"BMJ Open Respir Res"},{"issue":"3","key":"10.1016\/j.jcf.2025.12.016_bib0044","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/rccm.201604-0893OC","article-title":"Comparison of lung clearance index and Magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis","volume":"195","author":"Stahl","year":"2017","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:37:38Z","timestamp":1781782658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1569199325025470"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.12.016","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved ventilation inhomogeneity and lower LCI variability under ETI: Retrospective analysis in a pediatric cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}